Research programme: insulin-like growth factor I gene therapy - Amsterdam Molecular Therapeutics

Drug Profile

Research programme: insulin-like growth factor I gene therapy - Amsterdam Molecular Therapeutics

Alternative Names: AMT-070; IGF-1 gene therapy - Amsterdam Molecular Therapeutics

Latest Information Update: 16 Jul 2012

Price : $50

At a glance

  • Originator Digna Biotech; University of Navarra
  • Developer Amsterdam Molecular Therapeutics; University of Navarra
  • Class Antihyperglycaemics; Gene therapies; Growth factors
  • Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Liver cirrhosis

Most Recent Events

  • 25 Nov 2009 No development reported - Preclinical for Cirrhosis in Netherlands (Parenteral)
  • 18 Nov 2009 No development reported - Preclinical for Cirrhosis in Spain (Parenteral)
  • 25 May 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top